EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Eur Acad Dermatol Venereol

Title: Journal of the European Academy of Dermatology and Venereology : JEADV

Publisher: Wiley

ISSN (Electronic): 1468-3083

ISSN (Print): 0926-9959

Publication date (Electronic): Nov 2020

Volume: 34

Issue: 11

Affiliations

[1 ] Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

[2 ] St John's Institute of Dermatology, London, UK.

[3 ] Academic Medical Centre Amsterdam, Amsterdam, Netherlands.

[4 ] University of Szeged, Szeged, Hungary.

[5 ] Office-Based Dermatology Practice, Geel, Belgium.

[6 ] Radboud University medical centre, Nijmegen, Netherlands.

[7 ] Unidad de Investigación, Fundación Piel Sana AEDV, Madrid, España.

[8 ] University of Verona, Verona, Italy.

[9 ] University hospital Copenhagen, København, Denmark.

[10 ] Guy's and St Thomas' NHS Foundation Trust, London, UK.

[11 ] Helsinki University Central Hospital, Helsinki, Finland.

[12 ] Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.

[13 ] International Federation of Psoriasis Associations (IFPA).

[14 ] Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

[15 ] Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

[16 ] University of Debrecen, Debrecen, Hungary.

[17 ] Aarhus University Hospital, Aarhus N, Denmark.

[18 ] Municipal Hospital Hietzing, Vienna, Austria.

[19 ] Dermatology, Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden.

[20 ] Department of Dermatology, Medical University of Warsaw, Warszawa, Poland.

[21 ] Office-Based Dermatology Practice, Mönchengladbach, Germany.

[22 ] Oslo University Hospital, Oslo, Norway.

[23 ] Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Article

DOI: 10.1111/jdv.16915

PubMed ID: 33349983

SO-VID: c347a489-52b1-49d7-b52c-6ad9dd62feb3

History

Data availability:

Comments

Comment on this article

Cited by 112

See all cited by